Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine August 2017, 58 (8) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

Fast tracking PSMA theranostics: Czernin and Eiber survey the rapid advance of prostate-specific membrane antigen–targeted diagnostics and radioligand therapy and address potential approaches to expediting regulatory approvals to advance these theranostics to wider clinical use.

Page 1186

Microdosing in drug development: Bergstrom looks at the theory and promise of microdosing, a regulatory concept introduced to facilitate exploratory studies in humans, and outlines challenges associated with extrapolation of low-mass microdoses to therapeutic levels.

Page 1188

177Lu-PSMA in prostate cancer: Fendler and colleagues provide an educational overview of 177Lu-prostate-specific membrane antigen radioligand therapy in metastatic castration-resistant prostate cancer, including patient stratification, protocols, medications, and follow-up.

Page 1196

Hyperpolarized MRI and cancer metabolism: Cho and colleagues highlight recent advances in hyperpolarized 13C MR spectroscopic imaging and its applications in noninvasively interrogating tumor metabolism.

Page 1201

Targeting PSMA in CRPC: Hadaschik and Boegemann offer perspective on prostate-specific membrane antigen–targeted radioligand therapy in metastatic castration-resistant prostate cancer and point to the need for data on relevant endpoints, predictive/prognostic biomarkers, and optimal treatment sequences.

Page 1207

89Zr-MSB0010853 biodistribution: Warnders and colleagues radiolabel the biparatopic Nanobody construct MSB0010853, which binds 2 different human epidermal growth factor receptor 3 epitopes, and use PET imaging to assess biodistribution and tumor uptake in mice.

Page 1210

11C-sarcosine PET tracer: Piert and colleagues assess this radiolabeled substrate of proton-coupled amino acid transporters as a new PET imaging probe and compare results with those from 11C-choline in 2 prostate cancer tumor xenograft models.

Page 1216

18F-FAZA human biodistribution and dosimetry: Savi and colleague describe the results of a phase I study designed to evaluate the biodistribution and dosimetry of this PET biomarker for regional tumor hypoxia in patients with non–small cell lung cancer.

Page 1224

Dose rates after NET imaging: Zhang-Yin and colleagues measure dose rates in patients immediately after PET/CT or SPECT/CT imaging for neuroendocrine tumors to determine whether additional radioprotective measures should be required.

Page 1230

PET, HIF2A PPGL, and polycythemia: Janssen and colleagues assess optimal imaging approaches using 4 different PET radiopharmaceuticals and CT/MRI in patients with pheochromocytoma/paraganglioma–polycythemia syndromes.

Page 1236

PET/CT response evaluation in NSCLC: Usmanij and colleagues determine the utility of 18F-FDG PET/CT after 1 treatment cycle in predicting response to chemotherapy in combination with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer.

Page 1243

Bone marrow uptake in HL: Zwarthoed and colleagues analyze clinicopathologic correlations and prognostic significance of different patterns of early 18F-FDG uptake in bone marrow in patients being treated for Hodgkin lymphoma.

Page 1249

Tumor metabolism in biliary tract cancer: Jo and colleagues use 18F-FDG PET to explore the prognostic value of tumor metabolism and chemotherapy-related changes in patients with advanced biliary tract cancer.

Page 1255

MRI and PET in DIPGs: Gerstner offers perspective on imaging in the diagnosis of diffuse intrinsic pontine gliomas and assessment of treatment response and provides context for an article on this topic in this issue of JNM.

Page 1262

PET and MRI ADC histogram in DIPG: Zukotynski and colleagues describe baseline 18F-FDG PET voxel characteristics in pediatric diffuse intrinsic pontine glioma and correlate these metrics with baseline MRI apparent diffusion coefficient histogram metrics, progression-free survival, and overall survival.

Page 1264

68Ga-THP-PSMA imaging: Young and colleagues detail the development and preclinical evaluation of a 68Ga radiotracer for imaging prostate-specific membrane antigen expression, with simple radiolabeling through addition of 68Ga generator eluate to a cold kit.

Page 1270

18F-FET kinetic modeling: Richard and colleagues compare different kinetic models in rats to determine which are more appropriate for PET imaging with 18F-FET, an artificial amino acid used for tumor delineation and grading.

Page 1278

SUVR prediction for PET probe: Arakawa and colleagues describe a mathematic method to predict influx rate constants, efflux rate constants, and nondisplaceable binding potentials of amyloid PET tracers and predict SUV ratios with time–activity curves of target/reference regions.

Page 1285

Glucose metabolic profile in epilepsy: Zhu and colleagues use 18F-FDG PET/CT imaging to evaluate the cerebral glucose metabolic profile in patients with epilepsy as part of an effort to elucidate correlations between metabolism and clinical severity.

Page 1293

Measuring longitudinal Aβ change: Bullich and colleagues determine in data from patients with mild cognitive impairment the optimal reference region that allows earlier detection of subtle amyloid-β changes using 18F-florbetaben PET.

Page 1300

PET/CT and autoimmune encephalitis: Solnes and colleagues examine the role of neuroimaging in the setting of autoimmune encephalitides, comparing the utility of 18F-FDG PET/CT with that of conventional brain imaging with MR.

Page 1307

RSNs from PET/fMRI: Savio and colleagues identify resting-state networks in 18F-FDG PET data and compare their spatial patterns with those obtained from simultaneously acquired resting-state functional MRI data in healthy subjects.

Page 1314

MMP tracer for aneurysm imaging: Toczek and colleagues describe the development and preclinical evaluation of a novel matrix metalloproteinase inhibitor–based SPECT/CT tracer, 99mTc-RYM1, and compare it with a more commonly used tracer in murine models of aortic aneurysm.

Page 1318

PET interpretation agreement in CS: Ohira and colleagues investigate inter- and intraobserver agreement in interpretation of 18F-FDG PET images in cardiac sarcoidosis and explore factors leading to discrepancies between readers.

Page 1324

11C-GMOM human dosimetry: van der Aart and colleagues perform studies estimating the whole-body PET radiation dose in humans with the methylguanidine-derivative agent 11C-GMOM.

Page 1330

Resin vs. glass spheres for 90Y TARE: Van der Gucht and colleagues compare survival of patients treated for unresectable hepatocellular carcinoma with 90Y-labeled resin- or glass-sphere transarterial radioembolization.

Page 1334

PET/CT in CS: Chareonthaitawee and members of an SNMMI/American Society of Nuclear Cardiology work group provide a consensus document on PET/CT in management of cardiac sarcoidosis, including indications for cardiac PET/CT, technical imaging recommendations, and optimal PET/CT clinical scenarios.

Page 1341

  • © 2017 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 58 (8)
Journal of Nuclear Medicine
Vol. 58, Issue 8
August 1, 2017
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Aug 2017, 58 (8) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Aug 2017, 58 (8) 8A;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • First Evaluation of PET-Based Human Biodistribution and Dosimetry of 18F-FAZA, a Tracer for Imaging Tumor Hypoxia
  • Joint SNMMI–ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring
  • Functional Imaging Signature of Patients Presenting with Polycythemia/Paraganglioma Syndromes
  • Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging
  • Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study
  • The Use of Microdosing in the Development of Small Organic and Protein Therapeutics
  • Preclinical Evaluation of RYM1, a Matrix Metalloproteinase–Targeted Tracer for Imaging Aneurysm
  • Human Epidermal Growth Factor Receptor 3–Specific Tumor Uptake and Biodistribution of 89Zr-MSB0010853 Visualized by Real-Time and Noninvasive PET Imaging
  • Prediction of the Clinical SUV Ratio in Amyloid PET Imaging Using a Biomathematic Modeling Approach Toward the Efficient Development of a Radioligand
  • MRI and PET: Noninvasive Tools to Probe the Biology of Diffuse Intrinsic Pontine Glioma
  • Acceleration of PSMA-Targeted Theranostics to the Clinic: Can Common Sense Prevail?
  • Resting-State Networks as Simultaneously Measured with Functional MRI and PET
  • The Predictive Value of Early In-Treatment 18F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non–Small Cell Lung Cancer
  • Preclinical Evaluation of 11C-Sarcosine as a Substrate of Proton-Coupled Amino Acid Transporters and First Human Application in Prostate Cancer
  • 177Lu-PSMA Radioligand Therapy for Prostate Cancer
  • Inter- and Intraobserver Agreement of 18F-FDG PET/CT Image Interpretation in Patients Referred for Assessment of Cardiac Sarcoidosis
  • Why Targeting of PSMA Is a Valuable Addition to the Management of Castration-Resistant Prostate Cancer: The Urologist’s Point of View
  • 68Ga-THP-PSMA: A PET Imaging Agent for Prostate Cancer Offering Rapid, Room-Temperature, 1-Step Kit-Based Radiolabeling
  • Determination of an Optimal Pharmacokinetic Model of 18F-FET for Quantitative Applications in Rat Brain Tumors
  • Resin Versus Glass Microspheres for 90Y Transarterial Radioembolization: Comparing Survival in Unresectable Hepatocellular Carcinoma Using Pretreatment Partition Model Dosimetry
  • Diagnostic Value of 18F-FDG PET/CT Versus MRI in the Setting of Antibody-Specific Autoimmune Encephalitis
  • Optimal Reference Region to Measure Longitudinal Amyloid-β Change with 18F-Florbetaben PET
  • Glucose Metabolic Profile by Visual Assessment Combined with Statistical Parametric Mapping Analysis in Pediatric Patients with Epilepsy
  • Correlation of 18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium
  • Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer
  • Human Dosimetry of the N-Methyl-d-Aspartate Receptor Ligand 11C-GMOM
  • Noninvasive Interrogation of Cancer Metabolism with Hyperpolarized 13C MRI
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire